Filter
511
Text search:
latent
tuberculosis
Featured
63
130
Language
Document type
360
54
48
22
10
8
5
2
1
Countries
42
20
19
14
11
9
8
8
8
8
7
6
6
6
5
5
4
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
135
66
17
10
6
4
4
Toolboxes
307
23
18
11
10
8
6
6
5
5
4
4
4
4
4
2
2
1
1
Rezumat. Definiţie. Epidemiologie. Etiologie. Ciclul de transmitere al tuberculozei. Patogenie si imunitate. Leziuni morfologice în tuberculoză.Modul PNEUMOLOGIE
1 mai 2013 – 30 aprilie 2014]Creditat prin decizia CMR nr. 6653/21.12.2012
Accessed at March 2014
Key populations brief.
Chapter 8, Prison and Health, published
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
The END TB Strategy
Accessed December 2017
Accessed December 2017
Ghidul Pacientului
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
This Global Plan builds on the previous edition, which laid out priority actions for 2018-2022, informed by global commitments member states endorsed at the 2018 United Nations High-Level Meeting (UNHLM) on TB. The resource needs estimates from this Global Plan include resources needed for implement
...
Key populations brief.
